Ultragenyx Pharmaceutical Stock Price, News & Analysis (NASDAQ:RARE)

$48.11 -0.11 (-0.23 %)
(As of 11/17/2017 04:00 PM ET)
Previous Close$48.22
Today's Range$46.35 - $49.27
52-Week Range$44.02 - $91.35
Volume549,091 shs
Average Volume434,245 shs
Market Capitalization$2.05 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.81

About Ultragenyx Pharmaceutical (NASDAQ:RARE)

Ultragenyx Pharmaceutical logoUltragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies. Its product candidates under biologics category include KRN23 (UX023) and recombinant human beta-glucuronidase (rhGUS) (UX003). Its product candidates under small-molecule category include UX007 and aceneuramic acid extended-release (Ace-ER) (UX001). It is also developing recombinant human protective protein cathepsin-A (rhPPCA). KRN23 is a fully human monoclonal antibody. rhGUS is an intravenous (IV) enzyme replacement therapy. UX007 is a substrate replacement therapy. It is developing Ace-ER for the treatment of GNE myopathy. rhPPCA is in preclinical development.


Industry, Sector and Symbol:
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Sector: Bio Therapeutic Drugs
  • Symbol: NASDAQ:RARE
  • CUSIP: N/A
  • Web: www.ultragenyx.com
Debt:
  • Current Ratio: 6.08%
  • Quick Ratio: 6.08%
Sales & Book Value:
  • Annual Sales: $130,000.00
  • Price / Sales: 15,761.58
  • Book Value: $8.58 per share
  • Price / Book: 5.61
Profitability:
  • Trailing EPS: ($6.97)
  • Net Income: ($245,870,000.00)
  • Return on Equity: -66.39%
  • Return on Assets: -57.79%
Misc:
  • Employees: 376
  • Outstanding Shares: 42,590,000
 

Frequently Asked Questions for Ultragenyx Pharmaceutical (NASDAQ:RARE)

What is Ultragenyx Pharmaceutical's stock symbol?

Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE."

How were Ultragenyx Pharmaceutical's earnings last quarter?

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) issued its quarterly earnings data on Thursday, November, 2nd. The biopharmaceutical company reported ($1.87) EPS for the quarter, meeting analysts' consensus estimates of ($1.87). The biopharmaceutical company earned $0.20 million during the quarter, compared to analyst estimates of $0.02 million. The business's quarterly revenue was up 81.8% compared to the same quarter last year. During the same period in the prior year, the company earned ($1.64) earnings per share. View Ultragenyx Pharmaceutical's Earnings History.

When will Ultragenyx Pharmaceutical make its next earnings announcement?

Ultragenyx Pharmaceutical is scheduled to release their next quarterly earnings announcement on Thursday, February, 15th 2018. View Earnings Estimates for Ultragenyx Pharmaceutical.

Where is Ultragenyx Pharmaceutical's stock going? Where will Ultragenyx Pharmaceutical's stock price be in 2017?

17 Wall Street analysts have issued twelve-month price objectives for Ultragenyx Pharmaceutical's shares. Their predictions range from $55.00 to $85.00. On average, they anticipate Ultragenyx Pharmaceutical's stock price to reach $71.60 in the next year. View Analyst Ratings for Ultragenyx Pharmaceutical.

What are Wall Street analysts saying about Ultragenyx Pharmaceutical stock?

Here are some recent quotes from research analysts about Ultragenyx Pharmaceutical stock:

  • 1. According to Zacks Investment Research, "Ultragenyx Pharmaceutical Inc. is involved in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. The Company's product pipeline include KRN23 (UX023) for the treatment of XLH, rhGUS (UX003) for the treatment of MPS 7, rhPPCA (UX004) for the treatment of galactosialidosis, Triheptanoin (UX007) for the treatment of LC-FAOD, Triheptanoin (UX007) for the treatment of Glut1 DS and SA-ER (UX001) for the treatment of HIBM which are in different clinical phases. Ultragenyx Pharmaceutical Inc. is headquartered in Novato, California. " (11/8/2017)
  • 2. J P Morgan Chase & Co analysts commented, "RARE’s 3Q report this afternoon was relatively uneventful aside from a few small updates: 1) RARE now has biopsy data from 6 adult patients that are included in the FDA review of burosumab (KRN23); 2) 48 week Phase 3 data for burosumab in adults will be available by YE17; and 3) the DMTX acquisition could close as early as Nov 7 th . Additionally, the company plans on hosting an analyst day in NY on December 4 th during which they plan on sharing some additional details regarding their earlier stage pipeline." (11/5/2017)
  • 3. Cowen and Company analysts commented, "We continue to see Pacira’s Exparel franchise as one of the most durable in specialty pharma and we believe that, over time, Exparel will continue to gain acceptance in the ortho community." (6/29/2017)
  • 4. Canaccord Genuity analysts commented, "INSM’s Ph3 Arikayce NTM CONVERT trial data is due ~September of this year." (5/8/2017)
  • 5. Jefferies Group LLC analysts commented, "uneventful" 2016 fourth quarter earnings call, as the company is expecting first commercial product by the end of 2017.Wang comments, "RARE 4Q16 EC was largely uneventful. Mgmt highlighted recent clinical progress in multiple programs and potentially first commercial product by YE17. We see overall favorable risk/reward heading into multiple data and regulatory catalysts in 2017, including KRN23 Ph3 data in adult XLH (1H17), BLA filing in the US, CHMP opinion in EU (2H17), Ace-ER Ph3 data in GNE myopathy (2H17)' RARE reported 4Q16 OpEx of $70.6M vs. our/consensus est of $74.8/69.9M. EPS was ($1.75) vs. our/consensus est of ($1.86/1.72). The company ended the quarter with $498.1M cash and guided that the cash should be sufficient to fund all clinical programs through Ph3 studies and potential launch. Mgmt guided to a continual increase in OpEx with a gradually slower YoY growth. Our $109 target is based on probability adjusted DCF. Risks include delay in EU conditional approval, less robust data, toxicity." (2/17/2017)

Who are some of Ultragenyx Pharmaceutical's key competitors?

Who are Ultragenyx Pharmaceutical's key executives?

Ultragenyx Pharmaceutical's management team includes the folowing people:

  • Daniel G. Welch, Independent Chairman of the Board (Age 59)
  • Emil D. Kakkis M.D. Ph.D., President, Chief Executive Officer, Director (Age 57)
  • Shalini Sharp, Chief Financial Officer, Executive Vice President (Age 42)
  • Sunil Agarwal M.D., President - Research and Development (Age 47)
  • Karah Parschauer, Executive Vice President, General Counsel (Age 39)
  • Jayson Dallas M.D., Chief Commercial Officer and Executive Vice President (Age 49)
  • Dennis Karl Huang, Chief Technical Operations Officer, Executive Vice President (Age 52)
  • Thomas Kassberg, Chief Business Officer, Executive Vice President (Age 56)
  • John R. Pinion II, Chief Quality Operations Officer and Executive Vice President Analytical Sciences and Research (Age 51)
  • William E. Aliski, Independent Director (Age 69)

Who owns Ultragenyx Pharmaceutical stock?

Ultragenyx Pharmaceutical's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Capital International Investors (6.80%), Pictet Asset Management Ltd. (1.77%), First Trust Advisors LP (1.24%), Capital Guardian Trust Co. (1.22%), Eagle Asset Management Inc. (1.12%) and Rockefeller Financial Services Inc. (0.94%). Company insiders that own Ultragenyx Pharmaceutical stock include Emil D Kakkis, Shalini Sharp, Sunil Agarwal, Theodore Alan Huizenga and William Aliski. View Institutional Ownership Trends for Ultragenyx Pharmaceutical.

Who sold Ultragenyx Pharmaceutical stock? Who is selling Ultragenyx Pharmaceutical stock?

Ultragenyx Pharmaceutical's stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN, Jennison Associates LLC, Ameriprise Financial Inc., Schwab Charles Investment Management Inc., Iguana Healthcare Management LLC, Point72 Asset Management L.P., Rockefeller Financial Services Inc. and California State Teachers Retirement System. Company insiders that have sold Ultragenyx Pharmaceutical company stock in the last year include Shalini Sharp, Theodore Alan Huizenga and William Aliski. View Insider Buying and Selling for Ultragenyx Pharmaceutical.

Who bought Ultragenyx Pharmaceutical stock? Who is buying Ultragenyx Pharmaceutical stock?

Ultragenyx Pharmaceutical's stock was bought by a variety of institutional investors in the last quarter, including Capital International Investors, Pictet Asset Management Ltd., Abingworth LLP, Brown Advisory Inc., First Trust Advisors LP, State of Wisconsin Investment Board, Cowen Inc. and Prudential Financial Inc.. View Insider Buying and Selling for Ultragenyx Pharmaceutical.

How do I buy Ultragenyx Pharmaceutical stock?

Shares of Ultragenyx Pharmaceutical can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ultragenyx Pharmaceutical's stock price today?

One share of Ultragenyx Pharmaceutical stock can currently be purchased for approximately $48.11.

How big of a company is Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical has a market capitalization of $2.05 billion and generates $130,000.00 in revenue each year. The biopharmaceutical company earns ($245,870,000.00) in net income (profit) each year or ($6.97) on an earnings per share basis. Ultragenyx Pharmaceutical employs 376 workers across the globe.

How can I contact Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical's mailing address is 60 Leveroni Ct, NOVATO, CA 94949-5746, United States. The biopharmaceutical company can be reached via phone at +1-415-4838800 or via email at [email protected]


MarketBeat Community Rating for Ultragenyx Pharmaceutical (NASDAQ RARE)

Community Ranking:  3.7 out of 5 (star star star)
Outperform Votes:  448 (Vote Outperform)
Underperform Votes:  157 (Vote Underperform)
Total Votes:  605
MarketBeat's community ratings are surveys of what our community members think about Ultragenyx Pharmaceutical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Ultragenyx Pharmaceutical (NASDAQ:RARE)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 8 Hold Ratings, 8 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Hold (Score: 2.41)
Consensus Price Target: $71.60 (48.83% upside)

Consensus Price Target History for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Price Target History for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Analysts' Ratings History for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/16/2017Canaccord GenuitySet Price TargetBuy$83.00 -> $80.00N/AView Rating Details
11/15/2017Cowen and CompanyReiterated RatingBuyN/AView Rating Details
11/5/2017J P Morgan Chase & CoReiterated RatingBuy$76.00N/AView Rating Details
11/3/2017Robert W. BairdLower Price TargetOutperform$85.00 -> $80.00N/AView Rating Details
10/6/2017Morgan StanleyReiterated RatingEqual Weight$69.00 -> $71.00N/AView Rating Details
9/14/2017WedbushUpgradeNeutral -> Outperform$62.00HighView Rating Details
9/6/2017Barclays PLCInitiated CoverageEqual Weight$60.00HighView Rating Details
8/23/2017Jefferies Group LLCSet Price TargetHold$62.00LowView Rating Details
8/23/2017JMP SecuritiesLower Price TargetMarket Outperform$90.00 -> $80.00LowView Rating Details
8/23/2017Stifel NicolausReiterated RatingBuy$95.00 -> $85.00HighView Rating Details
8/23/2017Leerink SwannReiterated RatingOutperform$89.00 -> $83.00HighView Rating Details
8/23/2017SunTrust Banks, Inc.DowngradeBuy -> Hold$105.00 -> $55.00HighView Rating Details
8/16/2017Evercore ISIInitiated CoverageIn -> In-Line$63.00HighView Rating Details
8/8/2017HC WainwrightReiterated RatingNeutral -> Neutral$72.00 -> $75.00LowView Rating Details
7/27/2017Sanford C. BernsteinInitiated CoverageMarket Perform$72.00HighView Rating Details
3/23/2017Piper Jaffray CompaniesReiterated RatingOverweight -> NeutralHighView Rating Details
11/30/2016Citigroup Inc.DowngradeNeutral -> SellN/AView Rating Details
9/14/2016Credit Suisse GroupReiterated RatingBuy$101.00N/AView Rating Details
6/28/2016Bank of America CorporationInitiated CoverageBuy$72.00N/AView Rating Details
2/9/2016Sterne Agee CRTInitiated CoverageBuyN/AView Rating Details
(Data available from 11/17/2015 forward)

Earnings

Earnings History and Estimates Chart for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Earnings by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Earnings History by Quarter for Ultragenyx Pharmaceutical (NASDAQ RARE)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/14/2018($1.96)N/AView Earnings Details
11/2/2017Q3 2017($1.87)($1.87)$0.02 million$0.20 millionViewN/AView Earnings Details
7/27/2017Q2 2017($1.73)($1.72)$0.01 millionViewN/AView Earnings Details
5/4/2017Q1 2017($1.71)($1.63)$0.05 millionViewListenView Earnings Details
2/16/2017Q4 2016($1.72)($1.75)$0.05 million$0.01 millionViewN/AView Earnings Details
11/7/2016Q3($1.53)($1.64)$7.60 million$0.11 millionViewListenView Earnings Details
8/8/2016Q2($1.44)($1.46)$0.02 millionViewN/AView Earnings Details
5/9/2016Q1($1.29)($1.35)ViewN/AView Earnings Details
2/25/2016Q4($1.14)($1.42)ViewListenView Earnings Details
11/9/2015Q3($0.87)($1.03)ViewN/AView Earnings Details
8/13/2015Q215($0.63)($0.83)ViewListenView Earnings Details
5/11/2015Q1 15($0.54)($0.63)ViewListenView Earnings Details
3/25/2015Q414($0.53)($0.52)ViewListenView Earnings Details
11/10/2014Q314($0.46)($0.50)ViewN/AView Earnings Details
8/11/2014Q214($0.42)($0.45)ViewN/AView Earnings Details
5/12/2014Q114($0.37)($0.85)ViewN/AView Earnings Details
3/24/2014($0.38)($4.98)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ultragenyx Pharmaceutical (NASDAQ:RARE)
2017 EPS Consensus Estimate: ($7.23)
2018 EPS Consensus Estimate: ($6.55)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174($1.82)($1.69)($1.75)
Q2 20174($1.93)($1.59)($1.76)
Q3 20174($2.01)($1.62)($1.85)
Q4 20174($2.09)($1.67)($1.87)
Q1 20182($1.87)($1.75)($1.81)
Q2 20182($1.84)($0.52)($1.18)
Q3 20181($1.78)($1.78)($1.78)
Q4 20181($1.78)($1.78)($1.78)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Ultragenyx Pharmaceutical (NASDAQ:RARE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Ultragenyx Pharmaceutical (NASDAQ RARE)

Insider Ownership Percentage: 9.20%
Institutional Ownership Percentage: 95.97%
Insider Trades by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)
Institutional Ownership by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Insider Trades by Quarter for Ultragenyx Pharmaceutical (NASDAQ RARE)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/28/2017Emil D KakkisCEOBuy7,500$52.52$393,900.00View SEC Filing  
5/26/2017Theodore Alan HuizengaVPSell480$57.46$27,580.80View SEC Filing  
3/9/2017Theodore Alan HuizengaInsiderSell2,500$86.34$215,850.00View SEC Filing  
3/2/2017Shalini SharpCFOSell12,000$90.10$1,081,200.00View SEC Filing  
2/27/2017Shalini SharpCFOSell12,000$80.14$961,680.00View SEC Filing  
12/5/2016William AliskiDirectorSell6,000$78.19$469,140.00View SEC Filing  
11/9/2016Shalini SharpCFOSell24,000$71.20$1,708,800.00View SEC Filing  
10/19/2016Shalini SharpCFOSell12,000$61.40$736,800.00View SEC Filing  
10/14/2016Emil D KakkisCEOSell20,000$63.02$1,260,400.00View SEC Filing  
8/15/2016Emil D KakkisCEOSell20,000$67.61$1,352,200.00View SEC Filing  
7/21/2016Sunil AgarwalInsiderSell649$52.68$34,189.32View SEC Filing  
7/15/2016Emil D KakkisCEOSell20,000$50.85$1,017,000.00View SEC Filing  
6/20/2016Sunil AgarwalInsiderSell650$54.16$35,204.00View SEC Filing  
5/24/2016Sunil AgarwalInsiderSell650$66.00$42,900.00View SEC Filing  
5/16/2016Emil D KakkisCEOSell20,000$59.95$1,199,000.00View SEC Filing  
4/20/2016Sunil AgarwalInsiderSell649$70.53$45,773.97View SEC Filing  
4/15/2016Emil D KakkisCEOSell20,000$70.33$1,406,600.00View SEC Filing  
3/22/2016Sunil AgarwalInsiderSell650$61.45$39,942.50View SEC Filing  
2/22/2016Sunil AgarwalInsiderSell658$63.48$41,769.84View SEC Filing  
1/20/2016Sunil AgarwalinsiderSell585$72.83$42,605.55View SEC Filing  
12/31/2015Emil D. KakkisCEOSell20,000$114.52$2,290,400.00View SEC Filing  
12/22/2015Sunil AgarwalInsiderSell498$114.81$57,175.38View SEC Filing  
12/18/2015Theodore Alan HuizengainsiderSell1,500$110.55$165,825.00View SEC Filing  
8/20/2015Sunil AgarwalinsiderSell17,020$111.18$1,892,283.60View SEC Filing  
8/12/2015Thomas Richard KassbergSVPSell3,334$109.70$365,739.80View SEC Filing  
7/20/2015Shalini SharpCFOSell3,854$131.95$508,535.30View SEC Filing  
7/8/2015Thomas Richard KassbergSVPSell3,334$102.12$340,468.08View SEC Filing  
6/18/2015Shalini SharpCFOSell4,000$96.08$384,320.00View SEC Filing  
6/17/2015Theodore Alan HuizengaInsiderSell1,500$94.80$142,200.00View SEC Filing  
6/10/2015Thomas Richard KassbergSVPSell3,334$88.19$294,025.46View SEC Filing  
4/20/2015Shalini SharpCFOSell4,000$62.23$248,920.00View SEC Filing  
4/8/2015Thomas Richard KassbergSVPSell3,333$58.02$193,380.66View SEC Filing  
1/20/2015Shalini SharpCFOSell4,000$51.24$204,960.00View SEC Filing  
12/18/2014Shalini SharpCFOSell4,000$44.82$179,280.00View SEC Filing  
12/10/2014Thomas Richard KassbergSVPSell3,333$40.22$134,053.26View SEC Filing  
12/4/2014William AliskiDirectorSell6,000$42.16$252,960.00View SEC Filing  
11/20/2014Shalini SharpCFOSell4,000$44.07$176,280.00View SEC Filing  
11/12/2014Thomas Richard KassbergSVPSell3,333$41.85$139,486.05View SEC Filing  
10/8/2014Thomas Richard KassbergSVPSell3,333$53.26$177,515.58View SEC Filing  
9/18/2014Shalini SharpCFOSell4,000$56.00$224,000.00View SEC Filing  
9/10/2014Thomas Richard KassbergSVPSell3,333$54.82$182,715.06View SEC Filing  
9/3/2014Thomas Richard KassbergSVPSell20,000$53.91$1,078,200.00View SEC Filing  
8/18/2014Shalini SharpCFOSell4,000$53.97$215,880.00View SEC Filing  
7/14/2014Group Holdings (Sbs) Advis TpgInsiderSell488,820$37.60$18,379,632.00View SEC Filing  
1/31/2014Fmr LlcInsiderBuy175,000$21.00$3,675,000.00View SEC Filing  
1/30/2014Shalini SharpCFOBuy4,500$21.00$94,500.00View SEC Filing  
1/30/2014Thomas Richard KassbergSVPBuy1,500$21.00$31,500.00View SEC Filing  
1/30/2014William AliskiDirectorBuy5,000$21.00$105,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Latest Headlines for Ultragenyx Pharmaceutical (NASDAQ RARE)

Source:
DateHeadline
Ultragenyx Pharmaceutical Inc. (RARE) Given New $80.00 Price Target at Canaccord GenuityUltragenyx Pharmaceutical Inc. (RARE) Given New $80.00 Price Target at Canaccord Genuity
www.americanbankingnews.com - November 16 at 4:51 PM
Ultragenyx Pharmaceuticals (RARE) Buy Rating Reaffirmed at Cowen and CompanyUltragenyx Pharmaceutical's (RARE) Buy Rating Reaffirmed at Cowen and Company
www.americanbankingnews.com - November 15 at 11:36 PM
Ultragenyx Pharmaceutical Inc. (RARE) Receives Consensus Rating of "Hold" from BrokeragesUltragenyx Pharmaceutical Inc. (RARE) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - November 13 at 8:14 AM
 Brokerages Anticipate Ultragenyx Pharmaceutical Inc. (RARE) Will Announce Quarterly Sales of $100,000.00 Brokerages Anticipate Ultragenyx Pharmaceutical Inc. (RARE) Will Announce Quarterly Sales of $100,000.00
www.americanbankingnews.com - November 10 at 11:13 AM
ETFs with exposure to Ultragenyx Pharmaceutical, Inc. : November 8, 2017ETFs with exposure to Ultragenyx Pharmaceutical, Inc. : November 8, 2017
finance.yahoo.com - November 9 at 12:16 PM
Ultragenyx Pharmaceutical Inc. (RARE) Rating Increased to Hold at Zacks Investment ResearchUltragenyx Pharmaceutical Inc. (RARE) Rating Increased to Hold at Zacks Investment Research
www.americanbankingnews.com - November 8 at 9:43 AM
Ultragenyx to Present at the Credit Suisse Healthcare ConferenceUltragenyx to Present at the Credit Suisse Healthcare Conference
finance.yahoo.com - November 7 at 9:20 AM
Ultragenyx Pharmaceutical, Inc. :RARE-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017Ultragenyx Pharmaceutical, Inc. :RARE-US: Earnings Analysis: Q3, 2017 By the Numbers : November 7, 2017
finance.yahoo.com - November 7 at 9:20 AM
Ultragenyx Completes Tender Offer and Acquisition of Dimension TherapeuticsUltragenyx Completes Tender Offer and Acquisition of Dimension Therapeutics
finance.yahoo.com - November 7 at 9:19 AM
Ultragenyx Pharmaceutical Inc. Forecasted to Earn Q1 2018 Earnings of ($1.75) Per Share (RARE)Ultragenyx Pharmaceutical Inc. Forecasted to Earn Q1 2018 Earnings of ($1.75) Per Share (RARE)
www.americanbankingnews.com - November 6 at 9:56 AM
Ultragenyx reports 3Q lossUltragenyx reports 3Q loss
finance.yahoo.com - November 6 at 6:23 AM
Ultragenyx Pharmaceutical Inc. (RARE) Receives Buy Rating from J P Morgan Chase & CoUltragenyx Pharmaceutical Inc. (RARE) Receives Buy Rating from J P Morgan Chase & Co
www.americanbankingnews.com - November 5 at 8:56 AM
Ultragenyx Pharmaceutical Inc. (RARE) PT Lowered to $80.00 at Robert W. BairdUltragenyx Pharmaceutical Inc. (RARE) PT Lowered to $80.00 at Robert W. Baird
www.americanbankingnews.com - November 5 at 7:16 AM
Ultragenyx Reports Third Quarter 2017 Financial Results and Corporate UpdateUltragenyx Reports Third Quarter 2017 Financial Results and Corporate Update
finance.yahoo.com - November 4 at 10:09 AM
Edited Transcript of RARE earnings conference call or presentation 2-Nov-17 9:00pm GMTEdited Transcript of RARE earnings conference call or presentation 2-Nov-17 9:00pm GMT
finance.yahoo.com - November 4 at 10:09 AM
Ultragenyx Pharmaceutical Inc. (RARE) Issues  Earnings ResultsUltragenyx Pharmaceutical Inc. (RARE) Issues Earnings Results
www.americanbankingnews.com - November 2 at 10:40 PM
Ultragenyx Pharma (RARE) and Kyowa Hakko Kirin Say FDA isnt Planning to Hold Advisory Committee Meeting for Burosumab BLAUltragenyx Pharma (RARE) and Kyowa Hakko Kirin Say FDA isn't Planning to Hold Advisory Committee Meeting for Burosumab BLA
www.streetinsider.com - November 2 at 8:11 AM
Ultragenyx and Kyowa Hakko Kirin Announce FDA Not Currently Planning to Hold Advisory Committee Meeting for Burosumab Biologics License ApplicationUltragenyx and Kyowa Hakko Kirin Announce FDA Not Currently Planning to Hold Advisory Committee Meeting for Burosumab Biologics License Application
finance.yahoo.com - November 2 at 8:11 AM
Ultragenyx Pharmaceuticals: RARE Opportunity To ProfitUltragenyx Pharmaceuticals: RARE Opportunity To Profit
seekingalpha.com - October 31 at 8:29 AM
Ultragenyx to Host Conference Call for Third Quarter 2017 Financial Results and Corporate UpdateUltragenyx to Host Conference Call for Third Quarter 2017 Financial Results and Corporate Update
finance.yahoo.com - October 31 at 8:29 AM
Comparing Ultragenyx Pharmaceutical (RARE) and Its CompetitorsComparing Ultragenyx Pharmaceutical (RARE) and Its Competitors
www.americanbankingnews.com - October 30 at 9:22 PM
Ultragenyx Pharmaceutical Inc. (RARE) Set to Announce Earnings on MondayUltragenyx Pharmaceutical Inc. (RARE) Set to Announce Earnings on Monday
www.americanbankingnews.com - October 30 at 3:28 AM
Ultragenyx Pharmaceutical (RARE) and The Competition Head-To-Head ReviewUltragenyx Pharmaceutical (RARE) and The Competition Head-To-Head Review
www.americanbankingnews.com - October 28 at 9:28 AM
Ultragenyx Pharma (RARE), Dimension (DMTX) Announce Expiration of HSR Waiting Period for Ultragenyxs ... - StreetInsider.comUltragenyx Pharma (RARE), Dimension (DMTX) Announce Expiration of HSR Waiting Period for Ultragenyx's ... - StreetInsider.com
www.streetinsider.com - October 27 at 12:56 PM
Ultragenyx Pharmaceutical is Now Oversold (RARE) - Nasdaq.com - NasdaqUltragenyx Pharmaceutical is Now Oversold (RARE) - Nasdaq.com - Nasdaq
www.nasdaq.com - October 27 at 12:56 PM
Is There Now An Opportunity In Ultragenyx Pharmaceutical Inc (RARE)?Is There Now An Opportunity In Ultragenyx Pharmaceutical Inc (RARE)?
finance.yahoo.com - October 22 at 6:08 AM
Zacks: Brokerages Anticipate Ultragenyx Pharmaceutical Inc. (RARE) Will Announce Quarterly Sales of $70,000.00Zacks: Brokerages Anticipate Ultragenyx Pharmaceutical Inc. (RARE) Will Announce Quarterly Sales of $70,000.00
www.americanbankingnews.com - October 21 at 9:46 AM
-$1.87 EPS Expected for Ultragenyx Pharmaceutical Inc. (RARE) This Quarter-$1.87 EPS Expected for Ultragenyx Pharmaceutical Inc. (RARE) This Quarter
www.americanbankingnews.com - October 19 at 6:24 AM
CRY Opens Wallet, LLYs JUNIPER Flops, MDXG Catches Eyes ... - NasdaqCRY Opens Wallet, LLY's JUNIPER Flops, MDXG Catches Eyes ... - Nasdaq
www.nasdaq.com - October 11 at 6:56 AM
Ultragenyx Pharma (RARE) Says FDA Accepts Burosumab BLA; Sets 04/17/18 PDUFA Date - StreetInsider.comUltragenyx Pharma (RARE) Says FDA Accepts Burosumab BLA; Sets 04/17/18 PDUFA Date - StreetInsider.com
www.streetinsider.com - October 11 at 6:56 AM
Ultragenyx and Kyowa Hakko Kirin Announce FDA Acceptance and Priority Review Designation of Burosumab’s Biologics License ApplicationUltragenyx and Kyowa Hakko Kirin Announce FDA Acceptance and Priority Review Designation of Burosumab’s Biologics License Application
finance.yahoo.com - October 11 at 6:56 AM
Ultragenyx Pharmaceutical Inc. (RARE) PT Raised to $71.00 at Morgan StanleyUltragenyx Pharmaceutical Inc. (RARE) PT Raised to $71.00 at Morgan Stanley
www.americanbankingnews.com - October 6 at 11:02 AM
Ultragenyx Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : RARE-US : October 4, 2017Ultragenyx Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : RARE-US : October 4, 2017
finance.yahoo.com - October 6 at 5:42 AM
Ultragenyx Comments on Dimension Therapeutics Announcement that Ultragenyxs Offer is a “Superior Proposal” - GlobeNewswire (press release)Ultragenyx Comments on Dimension Therapeutics' Announcement that Ultragenyx's Offer is a “Superior Proposal” - GlobeNewswire (press release)
globenewswire.com - October 3 at 11:26 AM
Ultragenyx to Acquire Dimension Therapeutics - GlobeNewswire (press release)Ultragenyx to Acquire Dimension Therapeutics - GlobeNewswire (press release)
globenewswire.com - October 3 at 11:26 AM
Dimension Shares Rise On Sale to Ultragenyx - Biotech MoversDimension Shares Rise On Sale to Ultragenyx - Biotech Movers
finance.yahoo.com - October 3 at 11:26 AM
Ultragenyx Comments on Dimension Therapeutics’ Announcement that Ultragenyx’s Offer is a “Superior Proposal”Ultragenyx Comments on Dimension Therapeutics’ Announcement that Ultragenyx’s Offer is a “Superior Proposal”
www.nasdaq.com - October 2 at 10:05 AM
Gene Therapy: A Big Week for Many NamesGene Therapy: A Big Week for Many Names
finance.yahoo.com - September 25 at 3:32 PM
Ultragenyx Pharmaceutical Inc. (RARE) Given Average Rating of "Hold" by BrokeragesUltragenyx Pharmaceutical Inc. (RARE) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - September 24 at 6:48 AM
Ultragenyx Pharmaceutical: A Pullback And Upcoming Regulatory Catalysts - Seeking AlphaUltragenyx Pharmaceutical: A Pullback And Upcoming Regulatory Catalysts - Seeking Alpha
seekingalpha.com - September 22 at 3:30 PM
Ultragenyx Pharmaceutical Inc. (RARE) Rating Reiterated by Robert W. BairdUltragenyx Pharmaceutical Inc. (RARE) Rating Reiterated by Robert W. Baird
www.americanbankingnews.com - September 19 at 3:52 PM
Brokers Offer Predictions for Ultragenyx Pharmaceutical Inc.s Q2 2018 Earnings (RARE)Brokers Offer Predictions for Ultragenyx Pharmaceutical Inc.'s Q2 2018 Earnings (RARE)
www.americanbankingnews.com - September 18 at 5:16 AM
Todays Research Reports on Trending Tickers: bluebird bio and Ultragenyx PharmaceuticalToday's Research Reports on Trending Tickers: bluebird bio and Ultragenyx Pharmaceutical
finance.yahoo.com - September 15 at 3:26 PM
Ultragenyx Pharmaceuticals (RARE) CEO Emil Kakkis Presents at Baird 2017 Global Healthcare Conference (Transcript) - Seeking AlphaUltragenyx Pharmaceutical's (RARE) CEO Emil Kakkis Presents at Baird 2017 Global Healthcare Conference (Transcript) - Seeking Alpha
seekingalpha.com - September 15 at 8:01 AM
Ultragenyx Pharmaceutical Inc. (RARE) Stock Rating Upgraded by WedbushUltragenyx Pharmaceutical Inc. (RARE) Stock Rating Upgraded by Wedbush
www.americanbankingnews.com - September 14 at 9:35 AM
Ultragenyxs Burosumab Positive in Phase II for XLH and TIO - Nasdaq - NasdaqUltragenyx's Burosumab Positive in Phase II for XLH and TIO - Nasdaq - Nasdaq
www.nasdaq.com - September 13 at 3:31 PM
Ultragenyx's Burosumab Positive in Phase II for XLH and TIOUltragenyx's Burosumab Positive in Phase II for XLH and TIO
finance.yahoo.com - September 13 at 8:12 AM
Ultragenyx Pharmaceutical Inc. (RARE) Expected to Post Quarterly Sales of $70,000.00Ultragenyx Pharmaceutical Inc. (RARE) Expected to Post Quarterly Sales of $70,000.00
www.americanbankingnews.com - September 13 at 8:04 AM
Ultragenyx Pharmaceutical Inc. (RARE) Receives "Buy" Rating from Canaccord GenuityUltragenyx Pharmaceutical Inc. (RARE) Receives "Buy" Rating from Canaccord Genuity
www.americanbankingnews.com - September 12 at 9:28 PM
Ultragenyx and Kyowa Hakko Kirin Announce Additional Burosumab Data in X-Linked Hypophosphatemia (XLH) and Tumor-Induced Osteomalacia (TIO) at ASBMRUltragenyx and Kyowa Hakko Kirin Announce Additional Burosumab Data in X-Linked Hypophosphatemia (XLH) and Tumor-Induced Osteomalacia (TIO) at ASBMR
finance.yahoo.com - September 12 at 9:03 AM

Social Media

Financials

Chart

Ultragenyx Pharmaceutical (NASDAQ RARE) Chart for Friday, November, 17, 2017
Loading chart…

This page was last updated on 11/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.